Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 55
- Registration Number
- NCT01501383
- Locations
- 🇺🇸
Alabama, Northport, Alabama, United States
🇺🇸Arizona, Phoenix, Arizona, United States
🇺🇸Arizon, Phoenix, Arizona, United States
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
Phase 4
Terminated
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 121
- Registration Number
- NCT01467492
- Locations
- 🇺🇸
Alabama, Birmingham, Alabama, United States
🇺🇸California, San Francisco, California, United States
🇺🇸Connecticut, New Haven, Connecticut, United States
A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)
Phase 3
Terminated
- Conditions
- Hepatitis C
- Interventions
- Biological: Pegylated Interferon Alfa-2aDrug: Highly Active Antiretroviral Therapy (HAART)
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 185
- Registration Number
- NCT01467479
- Locations
- 🇺🇸
Alabama, Birmingham, Alabama, United States
🇺🇸California, San Francisco, California, United States
🇺🇸Connecticut, New Haven, Connecticut, United States
An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
Phase 2
Terminated
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 61
- Registration Number
- NCT01467505
- Locations
- 🇺🇸
Alabama, Birmingham, Alabama, United States
🇺🇸Arizona, Phoenix, Arizona, United States
🇺🇸California, Los Angeles, California, United States
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
Phase 3
Terminated
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 239
- Registration Number
- NCT01459913
- Locations
- 🇺🇸
California, San Francisco, California, United States
🇺🇸Pennsylvania, Hershey, Pennsylvania, United States
🇺🇸Virginia, Fairfax, Virginia, United States
VX-770 Expanded Access Program
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Registration Number
- NCT01381289
Drug-Drug Interaction Study Between Telaprevir and Buprenorphine
Phase 1
Completed
- Conditions
- Opioid-Related DisordersHepatitis C
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT01275599
Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 21
- Registration Number
- NCT01262352
Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 312
- Registration Number
- NCT01225211
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 48
- Registration Number
- NCT01216046
- Locations
- 🇺🇸
PRA, Lenexa, Kansas, United States